Navamedic's Glucomed gets nod from CHMP
Lysaker, Norway-based Navamedic says that its osteoarthritis treatment Glucomed/Flexove (glucosamine HCl) has been recommended for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA), dispelling doubts about the product which surfaced after certain European Union member state health authorities gave it bad reviews.
A formal approval is expected from a Standing Committee of the European Union Commission in the next three months, which will be valid for all 25 EU members, and Navamedic is preparing for product launches in several new markets next year.
The firm's chief executive, Oyvind Brekke, said that "the decision concludes the discussion regarding the efficacy of Glucomed/Flexove, confirming that our product has a positive risk/benefit ratio, which means that it is effective and safe in symptom relief in osteoarthritis."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze